NEW YORK, Sept. 23, 2024 /PRNewswire/ — DailyPay, a United States-based worktech company and leading provider of earned wage access (EWA), is expanding globally. Beginning this fall, DailyPay, an award-winning provider of EWA services, will have an EWA offering available in the United Kingdom, marking the company’s first foray outside the U.S. Read...
Read More“We’ve been working on this platform for over a decade and this is a groundbreaking version of our R&D platform. We’re ushering indoor agriculture into the AI age. Plenty’s new Wyoming facility is set to double our research capacity,” says Arama Kukutai, CEO of Plenty, commenting on the vertical farming company’s recent expansion announcement. Read...
Read MoreAccording to a new report, French consumers lost €2.92 billion less (€5.14 billion total) to scammers in 2024 than they did a year ago (€8.06 billion). While that represents a more than 33% decline, it still means the French lost a sum equivalent to 0.2% of the nation’s GDP to scams in the last year alone. The findings from the Global Anti-Scam Alliance (GASA) and BioCatch – the global leader in digital fraud detection and financial crime prevention powered by behavioral intelligence – show a nation making progress in its fight against scams but still suffering greatly from an onslaught of attacks. Read...
Read MoreIt seems like almost every day at the moment that an asset manager is announcing a new partnership to make alternatives go mainstream. BlackRock’s acquisition of Preqin in the summer fired the starting gun on this rush to alternatives, by signaling an intention to index private markets. Last week saw Apollo & State Street launch a “private credit” ETF (well, up to 15% of the portfolio can be private). This week saw BlackRock announce a partnership with Partners Group for an all-in-one private markets product. Read...
Read MoreJERUSALEM, Sept. 20, 2024 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using the Alpha DaRT. Read more...
Read More
